Free Trial

Elanco Animal Health Q2 2023 Earnings Report

Elanco Animal Health logo
$12.48 -1.00 (-7.42%)
(As of 12/3/2024 05:45 PM ET)

Elanco Animal Health EPS Results

Actual EPS
$0.18
Consensus EPS
$0.05
Beat/Miss
Beat by +$0.13
One Year Ago EPS
$0.36

Elanco Animal Health Revenue Results

Actual Revenue
$1.06 billion
Expected Revenue
$1.04 billion
Beat/Miss
Beat by +$19.36 million
YoY Revenue Growth
-10.20%

Elanco Animal Health Announcement Details

Quarter
Q2 2023
Time
Before Market Opens
Lock in this share price before 12/5 (Ad)

When the team that built Zillow into a $16B real estate leader launches a new company, it’s worth paying attention. That’s why top firms like SoftBank and Maveron have already backed their latest venture, a company that’s transforming the $1.3 trillion vacation home market.

Learn more about becoming a shareholder in this real estate disruptor before their share price chang

Elanco Animal Health Earnings Headlines

I was wrong. Dead wrong.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Elanco Animal Health (NYSE:ELAN) Stock Rating Upgraded by Leerink Partnrs
See More Elanco Animal Health Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Elanco Animal Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Elanco Animal Health and other key companies, straight to your email.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

View Elanco Animal Health Profile

More Earnings Resources from MarketBeat